Sustained release injectable composition containing finasteride
A sustained-release injectable composition with finasteride, using biodegradable polymers, addresses the need for extended hair loss treatment and prostatic hyperplasia management by maintaining constant blood concentration and reducing daily administration burdens.
Patent Information
- Application Number
- JP2020213698
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-12-23
- Filing Date
- 2020-12-23
- Publication Date
- 2024-11-27
- Estimated Expiration
- 2040-12-23
AI Technical Summary
Conventional oral hair loss treatments with finasteride require daily administration to maintain efficacy, posing inconvenience and safety risks, especially for women of childbearing age and pregnant women, and lack a suitable injectable form that sustains drug release for an extended period.
A sustained-release injectable composition containing finasteride, formulated with biodegradable polymers and specific particle sizes, provides a controlled release pattern for 1 to 3 months, maintaining a constant blood concentration without initial over-release and reducing foreign body sensation.
The composition ensures continuous hair loss treatment and benign prostatic hyperplasia management for an extended period, minimizing side effects and handling inconveniences by providing a stable, long-term drug release through subcutaneous injection.
Smart Images

Figure 0007590759000007 
Figure 0007590759000008 
Figure 0007590759000009
Abstract
Description
[Technical field]
[0001] The present invention relates to a sustained release injectable composition containing finasteride, and more specifically, to a sustained release injectable composition containing finasteride, which can maintain the effect of drug administration of finasteride for a long period of time when injected into the body in an injection form. [Background technology]
[0002] Currently, oral preparations of finasteride and dutasteride are used in Korea to treat male pattern baldness. These hair loss treatments block the 5-α-reductase inhibitor that converts testosterone into dihydrotestosterone (DHT), thereby suppressing the production of DHT, a powerful male hormone, and thus suppressing the shrinkage of hair roots caused by DHT on the scalp, thereby treating androgenetic alopecia.
[0003] 5-α-reductase inhibitors are divided into Type 1 and Type 2, with Type 1 distributed in the scalp and sebaceous glands, and Type 2 distributed in the scalp and prostate. Finasteride blocks only Type 2 5-α-reductase inhibitors, while dutasteride blocks both Type 1 and Type 2. Due to this mechanism, dutasteride is known to have a stronger DHT suppression effect than finasteride. However, due to the higher incidence of side effects with dutasteride during the first year of use, finasteride is currently the most widely used hair loss treatment and is the only one approved by the FDA, so it has an advantage over dutasteride in terms of safety.
[0004] As in Patent Document 1, conventional oral hair loss treatment agents have a problem that they can only be effective when taken every day for more than three months, and when the drug is discontinued, the drug loses efficacy and the patient returns to the original state. Therefore, in order to maintain the drug's efficacy and maintain the hair loss treatment effect, the drug must be taken continuously every day at the scheduled time.
[0005] Hair loss treatment drugs such as dutasteride and finasteride are designated as contraindicated drugs for women of childbearing age and pregnant women because they are related to male hormones, and if hair loss treatment drugs are exposed to women of childbearing age and pregnant women, they may cause abnormalities in the external genitalia of male fetuses, which may lead to the birth of malformed children, so hair loss treatment drugs must be stored and handled with care.In addition, drugs can be absorbed through the skin and can affect fetuses, so they must not be touched, and those who take them and live with women of childbearing age and pregnant women in the vicinity must be especially careful when handling them.
[0006] Conventional hair loss treatments such as dutasteride and finasteride are only available in oral dosage forms.
[0007] The drug is prescribed at the hospital, the user takes it home and keeps it, and takes it continuously every day on time in order for the hair loss treatment to be effective.
[0008] This method of use causes inconvenience when using hair loss treatments, which are taboo for women of childbearing age and pregnant women.
[0009] Therefore, there is an urgent need to develop a hair loss treatment that utilizes finasteride, which is recognized as a more stable hair loss treatment, can maintain its efficacy for more than one month with a single dose, and can be administered by subcutaneous injection rather than orally, making it easy to store and handle. [Prior art documents] [Patent documents]
[0010] [Patent Document 1] Korean Patent Publication No. 10-2016-0002411 Summary of the Invention [Problem to be solved by the invention]
[0011] The object of the present invention is to provide a sustained release injectable composition containing finasteride.
[0012] Another object of the present invention is to provide an injectable composition containing finasteride which, when injected in the form of an injection, is free from initial excessive release and can maintain a constant blood concentration for a long period of time.
[0013] Another object of the present invention is to provide an injectable composition that is easy to store and handle because it is provided in a dosage form that can be injected subcutaneously rather than orally, and does not require storage by the user, and can demonstrate the therapeutic effects of finasteride for hair loss and benign prostatic hyperplasia by directly administering it at a hospital.
[0014] Another object of the present invention is to provide a composition for subcutaneous injection that can maintain the therapeutic effects for hair loss and benign prostatic hyperplasia for one to three months.
[0015] Another object of the present invention is to provide an injectable composition containing sustained release particles comprising finasteride, which maintain a long-term drug administration effect for one to three months, and which has an average particle size adjusted to a uniform micro-sized size to regulate the release of the drug and maintain a constant effective drug concentration, which can be applied to an injectable solution composed of particles of uniform size and which can reduce foreign body sensation and pain when administered to a patient as an injection. [Means for solving the problem]
[0016] In order to achieve the above object, a sustained release injectable composition containing finasteride according to one embodiment of the present invention is a sustained release injectable composition containing finasteride, which is injected into the body and continuously releases finasteride, and the released finasteride has a maximum blood concentration (C max ) versus initial blood concentration (C int ) ratio is 2 to 11.
[0017] The maximum blood concentration of finasteride (C max ) may be 0.3 μg / L to 0.5 μg / L for each mg of finasteride administered.
[0018] The area under the concentration curve of finasteride (AUC 0-t ) can be 70 (μg*h / L) to 100 (μg*h / L) per mg of finasteride administered.
[0019] The sustained release injectable composition has a controlled drug release rate, does not have an initial over-release problem, and forms a sustained release pattern for 1 to 3 months, thereby suppressing the production of DHT and testosterone.
[0020] The injectable composition comprises a suspending medium, which may comprise an isotonic agent, a suspending agent, and a solvent.
[0021] The isotonicity agent may be selected from the group consisting of D-Mannitol, Maltitol, Sorbitol, Lactitol, Xylitol, Sodium chloride, and mixtures thereof.
[0022] The suspending agent may be selected from the group consisting of sodium carboxymethylcellulose, polysorbate 80, starch, starch derivatives, polyhydric alcohols, chitosan, chitosan derivatives, cellulose, cellulose derivatives, collagen, gelatin, hyaluronic acid (HA), alginic acid, algin, pectin, carrageenan, chondroitin, chondroitin sulfate, dextran, dextran sulfate, polylysine, titin, fibrin, agarose, fluran, xanthan gum, and mixtures thereof.
[0023] In the present invention, the term "injection" refers to the injection of a medicinal solution into the skin, subcutaneously, intramuscularly, intravenously, or intraarterially using a syringe. Specifically, since the pharmaceutical composition of the present invention exhibits the efficacy of preventing hair loss or promoting hair growth, the injection may be a subcutaneous injection, but is not limited thereto. The syringe may be any syringe that can administer a medicinal solution through a needle, as well as any syringe that can be used to administer the composition of the present invention subcutaneously.
[0024] The subcutaneous tissue is the area between the muscles and bones below the dermis layer, and contains a large amount of fat-containing adipocytes that give the human body flexibility and shape, can be used as energy, and is a place where arteries and lymphatic fluids circulate.
[0025] In the present invention, an isotonicity agent is a compound that is physiologically tolerable and imparts a suitable tonicity to the formulation to impede the essential flow of water across cell membranes in contact with the formulation.
[0026] In the present invention, administration means introducing a predetermined substance into an individual by a suitable method. In the present invention, the administration may be into subcutaneous tissue since the composition exhibits an effect of preventing hair loss or promoting hair growth when injected into an individual. Effect of the Invention
[0027] According to the sustained release injectable composition containing finasteride of the present invention, when it is injected in an injection form, there is no initial over-release of finasteride and a constant blood concentration of finasteride can be maintained for a long period of time, and when administered by subcutaneous injection, the hair loss treatment effect can be sustained for 1 to 3 months.
[0028] The injectable composition can control the release of the drug to maintain a constant effective drug concentration and reduce the foreign body sensation and pain when administered to a patient as an injection.
[0029] In addition, it is provided in a dosage form that can be injected subcutaneously rather than orally, so there is no need for the user to store it, and the finasteride treatment effects for hair loss and benign prostatic hyperplasia can be achieved by directly administering it at the hospital, making it easy to store and handle. [Brief description of the drawings]
[0030] [Figure 1] FIG. 1 is a SEM photograph of controlled release particles according to one embodiment of the present invention. [Diagram 2] FIG. 2 is a SEM photograph of controlled release particles according to one embodiment of the present invention. [Diagram 3] FIG. 3 is a SEM photograph of controlled release particles according to one embodiment of the present invention. [Figure 4] FIG. 4 shows the distribution measurement results of controlled release particles prepared according to one embodiment of the present invention. [Diagram 5] FIG. 5 shows the results of particle distribution measurement of a comparative example according to an embodiment of the present invention. [Figure 6] FIG. 6 shows the PK profile measurement results of a comparative example according to an embodiment of the present invention. [Figure 7] FIG. 7 shows the blood concentration transition in a comparative example according to an embodiment of the present invention. [Figure 8] FIG. 8 shows the PK profile of a comparative example according to an embodiment of the present invention when repeatedly administered over 28 days. [Figure 9] FIG. 9 shows the results of measuring the average blood concentration profile of controlled release particles according to one embodiment of the present invention. [Figure 10] FIG. 10 shows the results of measuring the average blood concentration profile of controlled release particles according to one embodiment of the present invention. [Figure 11] FIG. 11 shows the results of measuring the average blood concentration profile of controlled release particles according to one embodiment of the present invention. [Figure 12] FIG. 12 shows the average blood concentration profile measurement results for the finasteride content of an injectable composition according to one embodiment of the present invention. [Figure 13] FIG. 13 shows the measurement results for the mean blood concentration profile of finasteride and the rate of change in DHT after administration of an injectable composition according to one embodiment of the present invention. [Figure 14] FIG. 14 shows the measurement results for the blood concentration profile and DHT change rate of an oral dosage form according to one embodiment of the present invention. [Figure 15] FIG. 15 shows the measurement results for the average blood concentration profile of finasteride and the rate of change in DHT over a period of three months after administration of an injectable composition according to one embodiment of the present invention. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0031] DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS The present invention may be embodied in various different forms and should not be construed as being limited to the embodiments set forth herein.
[0032] Finasteride typically consists of a solid oral dosage form for oral administration, which requires users to take the finasteride dosage form at a fixed time each day and has the problem of having to store the drug at home for administration.
[0033] As mentioned above, finasteride is related to male hormones and is designated as a contraindicated drug for women of childbearing age and pregnant women. If a woman of childbearing age or pregnant women is exposed to the hair loss treatment drug, it can cause abnormalities in the external genitalia of the male fetus, which could result in the birth of a deformed child. Therefore, there is the inconvenience of having to take care in storing and handling the hair loss treatment drug.
[0034] Furthermore, when taken in a solid oral dosage form, there may be a problem with maintaining high blood levels of finasteride if taken daily.
[0035] In other words, when finasteride is taken orally, the maximum blood concentration (C max ) up to 46.30 μg / L, and if taken daily, it will maintain a high, sustained blood concentration of finasteride.
[0036] In situations where finasteride does not need to have the same maximum plasma concentration levels as the oral dosage form to demonstrate its drug effect, problems can arise with excessive exposure of the user to finasteride.
[0037] Thus, the present invention relates to sustained release particles containing finasteride that can be used in an injectable dosage form rather than an oral dosage form.
[0038] Specifically, the sustained release particles contain finasteride and a biodegradable polymer, are spherical in shape and have an average diameter of 35 μm to 55 μm.
[0039] The sustained release particles contain a biodegradable polymer and finasteride, and in this case, rather than being in a capsule-shaped dosage form, the composition in which the biodegradable polymer and finasteride are uniformly mixed is prepared as perfectly spherical sustained release particles, and the sustained release particles are characterized in that the finasteride is uniformly distributed within the sustained release particles.
[0040] Furthermore, when the subcutaneous injection composition of the present invention is injected into the body, the sustained release particles themselves are administered into the body, and the biodegradable polymer that constitutes the sustained release particles decomposes over time, thereby releasing the finasteride that was evenly distributed in the body.
[0041] As described above, finasteride released into the body can have the effect of preventing hair loss or promoting hair growth.
[0042] Also, its availability in an injectable form may overcome the storage and handling problems associated with providing it in a solid oral dosage form.
[0043] The controlled release particles have an average diameter of 35 μm to 55 μm, and the standard deviation of the average diameter is 3.0 to 5.5.
[0044] The present invention relates to sustained release particles prepared by the method for preparing sustained release particles described below, and as explained above, is characterized in that the biodegradable polymer and finasteride are evenly distributed, and the average diameter of the sustained release particles prepared is 35 μm to 55 μm, and the standard deviation for the average diameter is distributed at 3.0 to 5.5.
[0045] In other words, even though micro-sized particles are prepared, the standard deviation is only 3.0 to 5.5, so particles of approximately the same size can be prepared.
[0046] In the case of the solvent evaporation method, which is generally known as a method for preparing controlled release particles using polymers, the diameter range of the prepared particles varies. Therefore, in order to prepare particles having an average diameter of 35 μm to 55 μm as in the present invention, it is necessary to prepare controlled release particles, classify and remove particles that are too small or too large, and then use them, which results in a problem of a very low production yield.
[0047] In contrast, the controlled release particles of the present invention have an average particle size of 35 μm to 55 μm with a standard deviation of only 3.0 to 5.5, making it possible to mass-produce controlled release particles of approximately the same size, thus providing excellent production yield.
[0048] When the average particle size is 35 μm or less, the prepared sustained-release particles may have a small diameter of 20 μm or less, which may increase the possibility of being ingested by macrophages after injection into the human body, thereby affecting effective drug release and in vivo absorption. Also, when the particle size exceeds 55 μm, foreign body sensation and pain may increase when administering an injection, and the particle size distribution of the prepared particles becomes large, making it difficult to prepare sustained-release particles with a uniform particle size.
[0049] The controlled release particles of the present invention have a specific surface area of 0.14 m 2 / g~0.150m 2 / g, and the maximum blood concentration of finasteride after administration (C max ) is 0.9μg / L~10.0μg / L.
[0050] In addition, the maximum blood concentration (C max ) has a standard deviation of 0.5 to 5.
[0051] The controlled release particles according to one embodiment of the present invention are characterized in that they are completely spherical and have an evenly formed spherical surface. In this case, the specific surface area is 0.14 m 2 / g~0.150m 2 / g.
[0052] By having the above-mentioned specific surface area value, the maximum blood concentration (C max ) may indicate 0.9μg / L to 10.0μg / L.
[0053] Generally, when finasteride is taken orally, the effective concentration is reached one to two hours after ingestion, and due to the half-life of the drug, it is recommended that a healthy adult male take the drug for three days to maintain a constant concentration.
[0054] In other words, finasteride taken orally reaches its maximum blood concentration 1 to 2 hours after taking the drug. Cmax ) shows a high value of 42.87 μg / L, whereas the sustained release particles of the present invention can show a relatively very low maximum blood concentration value even after administration into the body.
[0055] Oral dosage forms show high maximum blood concentrations when taken, but because they have a relatively short half-life, daily administration is necessary to maintain effective concentrations. In addition, because oral dosage forms show high blood concentrations after taking the drug, there is the problem that finasteride must be taken at a level higher than the blood concentration at which the therapeutic effect actually appears.
[0056] On the other hand, the sustained release particles of the present invention, after administration in an injection dosage form, exhibit a maximum blood concentration of 0.9 μg / L to 10.0 μg / L, thereby demonstrating the therapeutic effect of finasteride administration, while at the same time relatively reducing the occurrence of side effects due to the administration of finasteride due to a lower blood concentration value than the oral dosage form.
[0057] However, since the maximum blood concentration value can vary depending on the amount of finasteride administered, it is difficult to make relative numerical comparisons.
[0058] Considering that finasteride taken in oral dosage form is usually taken at 1 mg, it was confirmed that the maximum blood concentration of the oral dosage form was 42.87 μg / L.
[0059] On the other hand, it was confirmed that the sustained release particles of the present invention showed a low maximum blood concentration value of 0.3 μg / L to 0.5 μg / L per 1 mg of finasteride based on the dose.
[0060] This means that although the maximum blood concentration value is extremely low compared to the oral dosage form, the long-lasting release effect of finasteride suppresses the production of DHT and testosterone, and can therefore be effective in preventing hair loss and treating benign prostatic hyperplasia.
[0061] In the case of oral dosage forms, there is the problem that finasteride must be taken every day due to its half-life, which means that the maximum blood concentration remains continuously high, which can lead to side effects.
[0062] On the other hand, in the case of the present invention, it has been confirmed that a very low maximum blood concentration value is observed when administered at the same dose of 1 mg as the oral dosage form, which makes it possible to minimize the occurrence of side effects, and by lowering the blood concentration value, it is possible to minimize the physical burden associated with the release of finasteride.
[0063] In addition, whereas oral dosage forms show a profile in which the blood concentration value initially reaches a maximum and then drops sharply, the injectable composition of the present invention is characterized by showing a sustained release pattern for 1 to 3 months, as the drug release rate is controlled by the sustained release particles, preventing the problem of initial over-release.
[0064] Such a sustained release pattern is a measure of the maximum blood concentration (C max ) versus initial blood concentration (C int ) is 2 to 11.
[0065] The fact that the initial blood concentration value is smaller than the maximum blood concentration value means that no initial over-release occurs, and because of the sustained release pattern, the maximum blood concentration value does not show a significant difference from the initial blood concentration value and is maintained within a certain range.
[0066] The sustained release particles of the present invention have an area under the drug concentration curve (AUC0-t) of 280 μg*h / L to 2000 μg*h / L after administration into the body.
[0067] When the blood concentration curve over time is determined, an area is formed under the curve, which is called the area under the time-drug concentration curve, or AUC for short.
[0068] The AUC is determined by the dose and clearance rate as follows: AUC = dose / clearance
[0069] The clearance (CLs) is a model-independent parameter, but has the following mathematical relationship with the elimination rate constant (K) and distribution volume (V): CLs = V × K
[0070] As can be seen from this relationship, clearance and distribution volume determine the drug elimination rate.
[0071] When clearance is constant, AUC is proportional to the dose, so if the drug dose is doubled, AUC increases by a factor of two. This concept also means that clearance is determined by AUC and dose.
[0072] Usually, the AUC can be calculated because the blood concentration as a function of the dose and time is known, and therefore the clearance can be calculated by the following formula. Drug clearance = dose / AUC
[0073] Assuming a one-compartment model and a constant amount of drug administered, the AUC can be easily calculated as follows: AUC=initial concentration (Co) / disappearance rate constant (K)
[0074] However, for drugs whose natural logarithm (log) value of drug concentration decreases linearly or nonlinearly with time, the AUC can be calculated by a method also known as the "trapezoidal rule."
[0075] The trapezoidal rule views the blood concentration versus time curve as a series of linked ladders, with adjacent measured blood concentrations connected by straight lines.
[0076] Even though the upper part of the trapezoid is a curve, if the time interval (the height of the trapezoid) is small, the curve can be considered as a straight line, and the error due to this becomes very small and can be ignored.
[0077] In this manner, the area of each trapezoid is easily calculated, and the sum of all trapezoid areas is the total area under the concentration curve.
[0078] The AUC calculation can be very usefully used to calculate the clearance of a drug. When calculating AUC using the trapezoidal rule, blood concentrations are not replaced by natural logarithmic values.
[0079] To calculate clearance, the AUC from time 0 to infinity is used. The AUC from time 0 to infinity is also calculated using the trapezoidal rule, which uses the AUC from time 0 to the time of the last concentration measurement plus the calculated area from the last measurement to infinity.
[0080] A large AUC value means a relatively high bioavailability, i.e., it is an index of the amount of absorption of the sustained release particles containing finasteride of the present invention when injected into the body.
[0081] In the case of oral dosage forms, unlike the sustained release particles of the present invention, the amount absorbed by the body is relatively reduced.
[0082] This is because, when the oral dosage form is taken, the blood concentration value is higher than that of the sustained release particles of the present invention, but the bioabsorption rate is lower than that of the sustained release particles of the present invention due to the influence of the half-life of the drug, etc.
[0083] In other words, although a high blood concentration is achieved after administration, the time that it remains in the body is short, resulting in a low absorption rate.
[0084] On the other hand, the sustained release particles of the present invention can exhibit a long-term drug release effect while maintaining a relatively low blood concentration, and therefore can exhibit excellent bioavailability. As a result, it can be said that the sustained release particles of the present invention can exhibit a superior finasteride administration effect compared to oral dosage forms.
[0085] The area under the concentration curve (AUC0-t) of finasteride may be 70 (μg*h / L) to 100 (μg*h / L) per 1 mg of administered finasteride.
[0086] As described above, considering that the area under the drug concentration curve of finasteride may vary depending on the content of finasteride contained in the injectable composition, the AUC 0-t The value of was confirmed.
[0087] As described above, it can be confirmed that the efficacy of finasteride administered is superior to that of the oral dosage form, being 70 (μg*h / L) to 100 (μg*h / L) per 1 mg of finasteride administered.
[0088] The finasteride-containing sustained release particles of the present invention can release finasteride continuously for one to three months when injected into the body.
[0089] The preparation of the sustained release particles containing finasteride of the present invention includes the following steps: 1) preparing a first mixture (S100); 2) preparing a second mixture (S200); 3) injecting the first mixture into a linear microchannel (S300); 4) injecting the second mixture into the microchannels on both sides or one side (S400); 5) collecting the controlled release particles (S500); 6) Stirring the collected controlled release particles (S600); 7) washing and drying the sustained release particles (S700).
[0090] More specifically, a method for preparing sustained release particles containing finasteride according to one embodiment of the present invention is described as follows.
[0091] 1) Step (S100) is a step of preparing a first mixture, in which a biodegradable polymer and finasteride are dissolved in an organic solvent to prepare a first mixture. The biodegradable polymer is selected from the group consisting of polylactic acid, polylactide, polylactic acid-co-glycolic acid, poly(lactide-co-glycolide) copolymer (PLGA), polyphosphazine, polyaminocarbonate, polyphosphoester, polyanhydride, polyorthoester, polycaprolactone, polyhydroxyvalerate, polyhydroxybutyrate, polyamino acid, and combinations thereof, and is preferably poly(lactide-co-glycolide) copolymer (PLGA), but is not limited to the above examples.
[0092] In addition, the organic solvent is one that is not miscible with water, and is, for example, any one or more selected from the group consisting of chloroform, chloroethane, dichloroethane, trichloroethane, and mixtures thereof, and preferably dichloromethane, but is not limited to these examples. It can be said that any organic solvent that can dissolve the biodegradable polymer and finasteride is not limited to the above examples and can be easily selected by a person skilled in the art and can be used.
[0093] The step 1) (S100) is to prepare a first mixture in which a biodegradable polymer and finasteride are dissolved, and the solvent is an organic solvent as described above. Finasteride and the biodegradable polymer are completely dissolved using an organic solvent by utilizing the solubility characteristics of the biodegradable polymer. After complete dissolution, the first mixture contains the biodegradable polymer and finasteride in a weight ratio of 2:1 to 15:1.
[0094] If the weight ratio of the biodegradable polymer to finasteride is less than 2:1, i.e., if the biodegradable polymer is contained in a ratio less than this, the weight ratio of the biodegradable polymer is low compared to the weight of finasteride, making it difficult to prepare sustained release particles in which finasteride is evenly distributed in spherical biodegradable polymer particles.If the weight ratio of the biodegradable polymer to finasteride is more than 15:1, i.e., if the biodegradable polymer is contained in an amount greater than this weight ratio, the finasteride content in the sustained release particles is low, making it necessary to administer a large amount of sustained release particles to administer the drug at the desired concentration.
[0095] More specifically, the biodegradable polymer in the first mixture is contained in an amount of 10% by weight to 20% by weight, and preferably 15% by weight, but is not limited to the above example.
[0096] Step 2) (S200) is a step of preparing a second mixture, and a surfactant is dissolved in water to prepare the second mixture. The surfactant can be used without limitation as long as it can help the biodegradable polymer solution to form a stable emulsion. Specifically, the surfactant is any one or more selected from the group consisting of nonionic surfactants, anionic surfactants, cationic surfactants, and mixtures thereof, more specifically, any one or more selected from the group consisting of methylcellulose, polyvinylpyrrolidone, lecithin, gelatin, polyvinyl alcohol, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene castor oil derivatives, sodium lauryl sulfate, sodium stearate, esteramines, linear diamines, puttyamines, and mixtures thereof, and preferably polyvinyl alcohol, but is not limited to the examples.
[0097] The steps 3) (S300) and 4) (S400) are steps of injecting the first mixture and the second mixture into a microchannel formed on a wafer to allow them to flow.
[0098] More specifically, the microchannels may be formed in a material selected from the group consisting of a silicon wafer or a polymer film, but is not limited to the above examples of materials, and any material capable of forming a microchannel may be used.
[0099] The polymer film may be selected from the group consisting of polyimide, polyethylene, fluorinated ethylene propylene, polypropylene, polyethylene terephthalate, polyethylene naphthalate, polysulfone, and mixtures thereof, but is not limited to the above examples.
[0100] For example, aluminum is deposited on a silicon wafer using an e-beam evaporator, and photoresist is patterned on the aluminum using photolithography.Then, aluminum is etched using the photoresist as a mask, and after the photoresist is removed, silicon is etched by DRIE (deep ion reactive etching) using the aluminum as a mask.After removing the aluminum, glass is sealed on the wafer by anodic bonding to manufacture the microchannel.
[0101] The microchannel has an average diameter of 35 μm to 55 μm, preferably 50 μm, but is not limited to the example. If the average diameter of the microchannel is 35 μm or less, the prepared sustained release particles may be small with a diameter of 20 μm or less, and may be preyed upon by macrophages after injection into the human body, which may affect effective drug release and in vivo absorption. In addition, if the size of the prepared sustained release particles exceeds 55 μm, foreign body sensation and pain may increase when administered as an injection, and the particle size distribution of the prepared particles becomes large, making it difficult to prepare sustained release particles with a uniform particle size.
[0102] However, the average diameter of the microchannel can be changed depending on the range of injection pressure. For example, when the diameter of the channel is 100 μm, the second mixture can be injected at a pressure of 1000 mbar to 2000 mbar, and the first mixture can be injected at a pressure of 200 mbar to 400 mbar.
[0103] The average diameter of the microchannel is closely related to the average diameter of the particles, but is also closely related to the injection pressure of the first mixture and the second mixture. Therefore, it is not limited to the above examples and can be changed depending on the average diameter of the particles to be prepared or the pressure conditions during injection.
[0104] The cross-sectional width (w) and cross-sectional height (d) of the microchannel are closely related to the average diameter (d') of the controlled release particles to be prepared. As shown in Fig. 8, the cross-sectional width (w) of the microchannel is in a ratio range of 0.7 to 1.3 to the average diameter (d') of the controlled release particles, and the cross-sectional height (d) of the microchannel is in a ratio range of 0.7 to 1.3 to the average diameter (d') of the controlled release particles.
[0105] In other words, once the average diameter (d') of the controlled release particles to be prepared is determined, the width (w) and height (d) of the microchannel cross section must be set accordingly within a ratio range of 0.7 to 1.3 of d' in order to prepare controlled release particles of the desired size.
[0106] The step 3) (S300) is for injecting the first mixture into a linear microchannel to allow it to flow, and the step 4) (S400) is for injecting the second mixture into a microchannel on one or both sides that is arranged to form an intersection with the linear microchannel to allow it to flow.
[0107] That is, the first mixture flows along a linear microchannel, and the second mixture flows along a microchannel that forms an intersection with the linear microchannel on both sides or one side of the linear microchannel, and merges with the flow of the first mixture.
[0108] In this case, when the first mixture is injected into the linear microchannel, it is injected under a constant pressure condition so that it flows at a constant flow rate. The pressure condition in this case is 500 mbar to 1500 mbar, preferably 1100 mbar, but is not limited to this example.
[0109] Furthermore, when the second mixture is injected into the microchannels on both sides or one side, it is injected under a constant pressure condition so that it flows at a constant flow rate. The pressure condition at this time is 1500 mbar to 2500 mbar, preferably 2200 mbar, but is not limited to this example.
[0110] In other words, the second mixture is flowed under higher pressure conditions in order to flow the second mixture, which forms an intersection with the first mixture, at a faster flow rate than the first mixture injected into the linear microchannel.
[0111] As described above, by making the flow rates of the first mixture and the second mixture different and making the flow rate of the second mixture faster than that of the first mixture, the second mixture, which has a relatively faster flow rate, compresses the first mixture at the point where the flows of the first mixture and the second mixture join together, and at this time, the repulsive force between the first mixture and the second mixture causes the biodegradable polymer and finasteride in the first mixture to form spherical sustained-release particles; more specifically, the sustained-release particles have a shape in which finasteride is evenly distributed in the spherical biodegradable polymer.
[0112] Step 5) (S500) is a step of collecting the controlled-release particles, and the controlled-release particles are collected in a water tank containing the second mixture to prevent aggregation between the initially generated controlled-release particles.
[0113] Step 5) (S500) uses the second mixture prepared in step 2) (S200), i.e., a mixed solution of surfactant and water. After preparing the second mixture in step 2) (S200), a portion of it is injected into a microchannel and the other portion is moved to a water tank in step 5) (S500) to prevent aggregation between the collected sustained-release particles.
[0114] The step 6) (S600) is a step of stirring the controlled release particles collected in the water tank, and the controlled release particles are stirred under a certain temperature condition and stirring speed to evaporate and remove the organic solvent present on the surface of the controlled release particles. At this time, the stirring conditions are a first stirring step at a speed of 150 rpm to 650 rpm for 0.5 to 1.5 hours at 15°C to 20°C, a second stirring step at a speed of 200 rpm to 1000 rpm for 2.0 to 6.0 hours at 35°C to 45°C after the first stirring step, and a third stirring step at a speed of 200 rpm to 1000 rpm for 0.5 to 1.5 hours at 15°C to 25°C after the second stirring step.
[0115] The stirring speed is different between the first and second stirring steps, and the stirring speed is faster in the second stirring step than in the first stirring step.
[0116] The temperature conditions as well as the stirring speed are characterized in that the temperature is increased in the second stirring step compared to the first stirring step, and the evaporation rate of the organic solvent present on the surface of the controlled release particles can be controlled by increasing the temperature stepwise. In other words, the organic solvent present on the surface of the controlled release particles can be gradually evaporated to prepare controlled release particles having a smooth surface.
[0117] The temperature of the first mixture and the second mixture when they flow through the microchannel is also 15°C to 20°C, and preferably 17°C. That is, after they flow through the microchannel and form an intersection to generate controlled release particles, the temperature is kept constant at a low temperature of 15°C to 20°C until the collected controlled release particles are subjected to the first stirring. Only by maintaining a low temperature during the preparation process of the controlled release particles can spherical particles be prepared and maintained. That is, without low temperature conditions, it is difficult to prepare uniform spherical particles.
[0118] Finally, step 7) (S700) is a step of washing and drying the controlled release particles. After stirring to remove all organic solvents from the surface of the controlled release particles, the controlled release particles are washed several times with sterilized and filtered purified water to remove surfactants remaining in the controlled release particles, and then freeze-dried.
[0119] The final sustained release particles are spherical biodegradable polymer sustained release particles in which the finasteride drug is evenly distributed, and contain the biodegradable polymer and finasteride in a weight ratio of 2:1 to 15:1.
[0120] The weight ratio of the biodegradable polymer and finasteride contained in the sustained release particles is the same as the weight ratio in the first mixture, which means that by preparing the sustained release particles and evaporating and removing all of the organic solvent, sustained release particles containing the biodegradable polymer and finasteride in the same weight ratio as in the first mixture can be prepared.
[0121] An injectable composition containing sustained release particles including finasteride according to another embodiment of the present invention may include sustained release particles including finasteride and a suspension solvent.
[0122] The injectable composition is in a form in which the sustained release particles are uniformly contained in the suspension solvent, and when the injectable composition is administered, the sustained release particles themselves are injected into the body, thereby achieving the long-term administration effect of finasteride.
[0123] More specifically, when the sustained release particles are injected into the body, the decomposition of the biodegradable polymer causes the release of finasteride. In this case, since the sustained release particles of the present invention are in the form of a uniform mixture of the biodegradable polymer and finasteride, the effect of administering a constant concentration of finasteride for a long period of time can be achieved.
[0124] In other words, a single injection of the injectable composition of the present invention allows finasteride to be continuously released in the body for one to three months, thereby solving the problem of having to take the drug every day and improving convenience for users.
[0125] The suspension medium comprises an isotonic agent, a suspending agent, and a solvent.
[0126] More specifically, the isotonicity agent may be selected from the group consisting of D-mannitol, maltitol, sorbitol, lactitol, xylitol, sodium chloride, and mixtures thereof, and is preferably D-mannitol, but is not limited to the above examples.
[0127] The suspending agent may be sodium carboxymethylcellulose, polysorbate 80, starch, starch derivatives, polyhydric alcohols, chitosan, chitosan derivatives, cellulose, cellulose derivatives, collagen, gelatin, hyaluronic acid (HA), alginic acid, algin, pectin, carrageenan, chondroitin, chondroitin sulfate, dextran, dextran sulfate, polylysine, titin, fibrin, agarose, fluran, xanthan gum, etc. gum), and mixtures thereof, and preferably sodium carboxymethylcellulose and polysorbate 80, but are not limited to the above examples.
[0128] The solvent may be water for injection, and any solvent that can be used as water for injection may be used without limitation.
[0129] (Preparation Example 1) [Preparation of a subcutaneous injection composition containing sustained release particles containing finasteride] 1. Preparation of sustained-release particles containing finasteride
[0130] Example 1 A first mixture was prepared by dissolving poly(lactide-co-glycolide) copolymer (PLGA) and finasteride in dichloromethane, where the poly(lactide-co-glycolide) copolymer in the first mixture was contained in a ratio of 15% by weight, and the weight ratio of poly(lactide-co-glycolide) copolymer to finasteride was 2:1.
[0131] A surfactant, polyvinyl alcohol, was mixed with water to prepare a second mixture containing 0.25% by weight of polyvinyl alcohol.
[0132] The first and second mixtures were injected into a microchannel formed on a silicon wafer to flow. In this case, in order to flow the first and second mixtures at a constant flow rate, the first mixture was flowed under a pressure condition of 1100 mbar, and the second mixture was flowed under a pressure condition of 2200 mbar. The temperature condition was maintained at 17°C.
[0133] The controlled release particles generated at the intersection where the first mixture flow and the second mixture flow joined were collected in a water tank containing the second mixture. The controlled release particles collected in the water tank were first stirred at 200 rpm to 400 rpm for 1 hour at 17°C, secondly stirred at 300 rpm to 800 rpm for 4 hours after increasing the temperature to 43°C, and thirdly stirred at 200 rpm to 1000 rpm for 1 hour at 20°C.
[0134] After the stirring was completed, the controlled release particles were washed several times with sterilized and filtered purified water, and then freeze-dried to prepare the controlled release particles.
[0135] Example 2 It was prepared similarly to Example 1, except that it contained a 9:1 weight ratio of poly(lactide-co-glycolide) copolymer and finasteride.
[0136] Example 3 It was prepared similarly to Example 1, except that it contained a 12:1 weight ratio of poly(lactide-co-glycolide) copolymer and finasteride.
[0137] 2. Preparation of Subcutaneous Injection Composition The sustained release particles prepared in Examples 1 to 3 were added to 2.0 ml of a suspension solvent per vial, and then uniformly suspended to prepare a composition for subcutaneous injection. The suspension solvent had the composition shown in Table 1 below.
[0138] [Table 1]
[0139] (Experimental Example 1) [Study of the properties of sustained release particles] In order to examine the properties of the controlled release particles according to one embodiment of the present invention, the properties of the prepared controlled release particles were confirmed using SEM photographs.
[0140] 1 to 3 are SEM photographs of the controlled release particles according to one embodiment of the present invention, and it can be seen that perfectly spherical controlled release particles are produced.
[0141] As a comparative example, sustained release particles were prepared using a solvent evaporation method, which is different from the preparation method of sustained release particles of the present invention. Finasteride and a biodegradable polymer were mixed in the same manner as in Preparation Example 1, and the mixture was injected into a syringe to prepare particles.
[0142] At this time, the stirring conditions were 40° C., 4 hours, and 1000 rpm to prepare particles.
[0143] The results of measuring the distribution of the controlled release particles prepared in Examples 1 to 3 and the Comparative Example are shown in FIG. 4 and FIG. The results of the measurements taken three times in Examples 1 to 3 are shown in Table 2 below.
[0144] [Table 2]
[0145] The particle diameter measurement results are shown in Table 2, and the standard deviations of the average diameters from the measurement results were confirmed to be 5.10, 3.39, and 4.65, respectively.
[0146] According to the above measurement results, it can be seen from the results of FIG. 4 and Table 2 that the controlled release particles prepared by the preparation method of the present invention are prepared as particles of similar size.
[0147] In addition, the specific surface area (m 2 / g) are 1.43 × 10 -1 , 1.46×10 -1 , and 1.43 × 10 -1 It was confirmed.
[0148] On the other hand, in the case of the comparative example, it was confirmed that the particle distribution was as shown in Table 3 below.
[0149] [Table 3]
[0150] As shown in the experimental results, it was confirmed that the prepared particles had various sizes, and the particle distribution was confirmed numerically with a standard deviation of 28.76.
[0151] In addition, the specific surface area (m 2 / g) is 1.13 x 10 -1 It was confirmed that the value was smaller than that of the particles according to the embodiment of the present invention.
[0152] (Experimental Example 2) [Pharmacokinetic characterization] The pharmacokinetic evaluation of the sustained release particles containing finasteride of the present invention and an injectable formulation containing the same was confirmed.
[0153] For the evaluation, a 1 mg oral dosage form of finasteride (Propecia) as a comparative example and the dosage forms of Examples 1 to 3 of the present invention were administered once to beagle dogs, after which the blood finasteride concentration was quantified using LC-MS / MS.
[0154] Pharmacokinetic (PKs) analysis was performed using WinNonlin software (ver. 8.0, Pharsight®, Certara®).
[0155] The main instruments and devices used in the analysis are as follows: Micro balance: SI-234, Denver Instrument ·Centrifuge: Centrifuge 5424, Eppendorf Vortex mixer: Model Genie-2, Scientific Industries Pipette (Auto pipette): Research plus 20μL, 100μL, 200μL, 1000μL, Eppendorf Screw caps, Microsolve Vials: Screw top 300μL, Microsolve Syringe dispenser: PB-600, HAMILTON Ultrasonic cleaner: 3510E-DTH, BRANSONIC (registered trademark) ·HPLC:1290 InfinityII, Agilent Technologies ·Mass spectrometer: 6490 Triple Quad LC / MS, Agilent Technologies Data processing system: Masshunter Workstation Ver B.07 (Agilent) The LC-MS / MS conditions are as follows.
[0156] - Chromatography conditions - ·HPLC:1290 InfinityII, Agilent Technologies Column: Phenomenex Kinetex C18, 1.7μm (100mm×2.1mm, ID) Column temperature: 40±0.5℃ Mobile phase: (A) 0.1% formic acid in distilled water (Formic acid in DW) (B) 100% methanol Isocratic elution mobile phase: A:B (40:60, v / v) ·Flow rate: 0.2mL / min ·Injection volume: 5μl Sample tray temperature: 10±5℃ Injector cleaning solution (strong): 70% methanol Injector cleaning solution (weak): 30% methanol ·Acquisition time: 8 minutes Autosampler run time: 8 minutes
[0157] -Mass detector requirements- ·Mass spectrometer: 6490 Triple Quad LC / MS, Agilent Technologies Ionization: Positive ion electrospray (ESI+) Mode: MRM Gas temperature: 200℃ Gas flow: 14L / min ·Inhaler: 20psi Capillary: 3000V
[0158] The PK profile of the Propecia single oral dose group (ID01-03) is shown in Figure 5. In addition, the blood concentration of finasteride over time after a single dose of Propecia is shown in Figure 6.
[0159] The PK parameters of the control drug administration group are shown in Table 4 below. The pharmacokinetic parameters of each test subject were calculated using the WinNonlin program (ver. 8.0, Pharsight (registered trademark), Certara Corporation) to calculate the area under the blood concentration-time curve (AUC ∞ ), maximum blood concentration (C max ), time to reach maximum blood concentration (T max ), elimination half-life (t 1 / 2 ), clearance (CL), and apparent volume of distribution (Vd) were calculated.
[0160] AUC ∞ is the AUC calculated from the plasma concentration up to the last measurable blood sampling time point after administration. t It is calculated by adding the area under the blood concentration-time curve obtained by extrapolating from the last measurable blood sampling time to infinity, and C max is the maximum blood concentration of each test subject, and t 1 / 2 was calculated as the time required for the initial dose of drug to decrease to half, i.e., 0.693 / k. CL was calculated using the relationship between drug dose and AUC, and Vd was calculated using the relationship between CL and k.
[0161] [Table 4]
[0162] For comparison with the injectable dosage form of the present invention, a simulation was performed based on the results of repeated administration of 1 mg QD of Propecia in a pharmacokinetic study (PK study), and a scenario of repeated administration for 28 days was set up. The results are shown in Figure 7.
[0163] Moreover, the injectable preparations of Examples 1 to 3 of the present invention were administered to beagle dogs, and the blood concentration profiles of finasteride were confirmed, as shown in FIGS. The detailed PK profile is shown in Table 5 below.
[0164] [Table 5]
[0165] According to the PK profile measurement results of the Comparative Example and Examples 1 to 3, in the case of the oral dosage form, the maximum blood concentration value of finasteride was higher than in Examples 1 to 3, but the AUC 0-t It can be seen that shows a small value.
[0166] Regarding the persistence of efficacy for 28 days, it was confirmed that Comparative Example 1 could only maintain an effective blood concentration that could maintain efficacy by taking the drug every day, whereas Preparation Examples 1 to 3 of the present invention maintained the efficacy for 28 days while maintaining the effective blood concentration.
[0167] (Preparation Example 2) [Preparation of a subcutaneous injection composition containing sustained release particles containing finasteride] Sustained release particles were prepared in the same manner as in Preparation Example 1 above, and then prepared as a composition for subcutaneous injection.
[0168] In this case, the sustained release particles were prepared so that each vial contained 10% (Example 1), 20% (Example 2), 40% (Example 3), 60% (Example 4), and 100% (Example 5) finasteride.
[0169] (Experimental Example 3) [Pharmacokinetic property evaluation using sustained release particles prepared in Preparation Example 2] Examples 1 to 3 prepared in Preparation Example 2 are the same as those in the previous pharmacokinetic evaluation experiment, and the results including the results for Examples 4 and 5 are shown in Table 6 below.
[0170] [Table 6]
[0171] The results are shown in AUC 0-t and C max The values for the sustained drug release effect over one month are shown in FIG.
[0172] In FIG. 12, the blue graph is for Example 1, orange is for Example 2, yellow is for Example 3, pink is for Example 4, and green is for Example 5.
[0173] As shown in FIG. 12, although the blood concentration values differ depending on the finasteride content of the administered injectable composition, the drug concentration profile confirms that there is no problem of initial over-release, and that finasteride is released continuously for one month.
[0174] In addition, the effectiveness of finasteride in preventing hair loss and treating benign prostatic hyperplasia can be confirmed based on its effect of suppressing the production of DHT.
[0175] The DHT production inhibitory effect was measured by measuring the rate of change (%) in concentration, with the average blood DHT concentration in beagle dogs before the experiment set as 100% as the standard.
[0176] The results of the experiment are shown in Figure 13, which shows the blood drug concentration and DHT production inhibition over one month in Example 5. It can be seen that sustained release of finasteride over one month has the effect of inhibiting DHT production.
[0177] Figure 14 shows the measurement results regarding the blood drug concentration value and the DHT production inhibitory effect following repeated administration of 1 mg QD of Propecia.
[0178] According to the above experimental results, the oral dosage form has an initial over-release when administered, and then the DHT inhibitory effect appears, but as time passes, the blood drug concentration drops rapidly, and the DHT inhibitory effect disappears. Therefore, it is troublesome to have to take the oral dosage repeatedly every day.
[0179] FIG. 15 shows whether sustained drug release is achieved for three months after administration of the sustained release particles of the present invention. It was confirmed that a constant amount of finasteride was released for three months without excessive release, and that the DHT production inhibitory effect was also maintained.
[0180] Although the preferred embodiments of the present invention have been described in detail above, the scope of the present invention is not limited thereto, and various modifications and improvements made by those skilled in the art using the basic concept of the present invention defined in the following claims also fall within the scope of the present invention.
Claims
1. A sustained release injectable composition containing sustained release particles containing finasteride, The controlled release particles have an average diameter of 35 μm to 55 μm and a standard deviation of the average diameter of 3.0 to 5.5 μm; The sustained release injectable composition injected into the body releases finasteride continuously, The released finasteride reaches a maximum blood concentration (C max ) initial blood concentration (C int ) is 2 to 11; The sustained release injectable composition has a controlled drug release rate and does not cause initial over-release. It forms a sustained release pattern for 1 to 3 months. Inhibits the production of DHT, A sustained release injectable composition comprising sustained release particles containing finasteride.
2. The maximum blood concentration of finasteride (C max ) is 0.3 μg / L to 0.5 μg / L per mg of administered finasteride; A sustained release injectable composition comprising sustained release particles containing finasteride according to claim 1.
3. The area under the concentration curve of finasteride (AUC) 0-t ) is 70 (μg*h / L) to 100 (μg*h / L) per 1 mg of administered finasteride, A sustained release injectable composition comprising sustained release particles containing finasteride according to claim 1.
4. The injectable composition comprises a suspension solvent, The suspension medium comprises an isotonic agent, a suspending agent, and a solvent; A sustained release injectable composition comprising sustained release particles containing finasteride according to claim 1.
5. The isotonicity agent is selected from the group consisting of D-Mannitol, Maltitol, Sorbitol, Lactitol, Xylitol, Sodium chloride, and mixtures thereof. A sustained release injectable composition comprising sustained release particles containing finasteride according to claim 4.
6. The suspending agent is selected from the group consisting of sodium carboxymethylcellulose, polysorbate 80, starch, starch derivatives, polyhydric alcohols, chitosan, chitosan derivatives, cellulose, cellulose derivatives, collagen, gelatin, hyaluronic acid (HA), alginic acid, algin, pectin, carrageenan, chondroitin, chondroitin sulfate, dextran, dextran sulfate, polylysine, titin, fibrin, agarose, fluran, xanthan gum, and mixtures thereof; A sustained release injectable composition comprising sustained release particles containing finasteride according to claim 4.
Citation Information
Patent Citations
Long-acting injection preparation of sterides 5 alpha-reductase inhibitor and preparation method thereof
CN102133180A
Sustained release composition containing finasteride
JP1996157370A
Finasteride-containing microparticles and their manufacturing method
JP2019534900A
Composite formulation comprising 5-α-reductase inhibitor-containing film coating layer and a process for the preparation thereof
KR1020160002411A
Composition and method of treating diseases and disorders of the prostate
US6277391B1
